TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02322346

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group S
Description: Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group LL
Description: Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group HL
Description: Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour.
Study: NCT03357341

Intervention type: OTHER
Intervention: electronic diary card
Description: Electronic diary card will be completed daily by subjects in COPD cohort.

Intervention type: OTHER
Intervention: CAT
Description: Subjects will be required to complete CAT monthly.

Intervention type: OTHER
Intervention: ACT
Description: Subjects will be required to complete ACT monthly.
Study: NCT01903174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroForm Breast Tissue Expander
Description: Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
Study: NCT01604408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: Administered SC
Study: NCT02114840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pronator quadratus preservation after volar plate fixation in wrist fractures
Description: Pronator quadratus preservation after volar plate fixation in wrist fractures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pronator quadratus repair after volar plate fixation in wrist fractures
Description: Pronator quadratus repair after volar plate fixation in wrist fractures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pronator quadratus nonrepair after volar plate fixation in wrist fractures
Description: Pronator quadratus nonrepair after volar plate fixation in wrist fractures
Study: NCT04900155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: Initially, hypolipidemic treatment with atorvastatin at a dose of 80 mg / day is prescribed from the first 24-96 hours of myocardial infarction in addition to standard therapy for the disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin-Ezetimibe
Description: In the absence of reaching the target level of LDL-C ≤1.4 mmol / L and ≥50% of the initial level after 4-6 weeks from the onset of myocardial infarction, patients additionally receive ezetimibe at a dose of 10 mg 1 time / day.
Study: NCT00849979

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Day 1 MDASI-GI Questionnaire

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaire
Description: Day 1 MDASI-GI Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Description: Open-ended, audiotaped interviews
Study: NCT00086957

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: 250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
Study: NCT01300897

Intervention type: PROCEDURE
Intervention: Cortical Evoked Potentials
Description: A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.

Intervention type: PROCEDURE
Intervention: Cortical Evoked Potentials
Description: A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.

Intervention type: PROCEDURE
Intervention: Transcranial motor evoked potentials
Description: A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.

Intervention type: PROCEDURE
Intervention: Transcranial motor evoked potentials
Description: A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.

Intervention type: PROCEDURE
Intervention: Translumbosacral motor evoked potentials
Description: A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.

Intervention type: PROCEDURE
Intervention: Translumbosacral motor evoked potentials
Description: A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
Study: NCT01403740

Intervention type: DRUG
Intervention: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin
Description: According to local clinical standards
Study: NCT04212338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Before intravitreal injection music intervention
Description: The patients in the Before-IVTI group listened to music for a period of 15 minutes 30 minutes before the injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: during intravitreal injection music intervention
Description: The patients in the During-IVTI group listened to music during the injection (approximately 5 minutes).
Study: NCT02081339

Intervention type: DRUG
Intervention: ranibizumab, aflibercept, pegaptanib, verteporphin
Study: NCT01542476

Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study: NCT02422953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Soya Blend (WSB)
Description: A monthly ration of 5 Kg of Wheat Soya Blend (WSB) will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wawa Mum
Description: Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient Powders (MNP)
Description: Children 24-59 months of age will receive a sachet of Micronutrient Powders (MNP) in alternate days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change and preventive health massages
Description: Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
Study: NCT00540436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325760A
Description: Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
Study: NCT04068558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNI-NAVA/sNIPPV
Description: Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sNIPPV/VNI-NAVA
Description: Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
Study: NCT01526018

Intervention type: BEHAVIORAL
Intervention: Podee bottle
Description: Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
Study: NCT00808717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10 mg vs. 80 mg before intervention
Study: NCT04152369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-microbial prophylaxis for an endourological procedure or ESWL
Description: anti-microbial prophylaxis according to urine culture results

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-microbial prophylaxis for an endourological procedure or ESWL
Description: anti-microbial prophylaxis according to urine culture results
Study: NCT02805309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral interventions
Description: The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control education program
Description: A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
Study: NCT01618630

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EAA Supplementation + Exercise Training
Description: Amino acids in drinks between meals for exercise training period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Exercise Training
Description: Placebo supplementation as drinks in between meals for exercise training period.
Study: NCT04125615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protected Time Intervention
Description: Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
Study: NCT00875888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous venovenous hemodialysis
Description: dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous venovenous hemodialysis
Description: dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
Study: NCT04251858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Scaling
Description: The individuals will be treated by a single periodontist and the scaling and root planing procedures will be performed on all teeth as follows: local anesthetic infiltrative type of the areas to be treated, dental and root scaling using Grace 5/6 carbon steel curettes, 11/12, 13/14 and MacCall 13/14, 17/18 curettes, according to their therapeutic indications. Polishing the quadrants treated with abrasive paste; oral hygiene instructions including Bass toothbrushing, dental floss and sometimes inter-dental brush.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction
Description: Oral hygiene instructions should be given to all study participants. Guidance on the most appropriate toothbrush, toothpaste and interproximal cleaning method.
Study: NCT00781690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evodial hemodialysers and Evodia blood lines
Description: Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
Study: NCT01949909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH-Alum50
Description: intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
Study: NCT00114101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT01636817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Administered subcutaneously (s.c., under the skin) once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Administered subcutaneously (s.c., under the skin) once weekly.
Study: NCT01949909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH-GLA2.5/50
Description: intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
Study: NCT01604408

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01636817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Administered subcutaneously (s.c., under the skin) once weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once weekly.
Study: NCT04755673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atrantil (Medical Food)
Description: All participants will be given 28 days supply of Atrantil. The impact of the intervention will be measured by daily symptom surveys as well as a hydrogen methane breath test administered at the end of the 28 days of treatment to identify if methane levels have changed.
Study: NCT00877617

Intervention type: BEHAVIORAL
Intervention: QOL Questionnaire
Description: Mailed survey.
Study: NCT03513536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrus-Based Aromatherapy
Description: This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint-Based Aromatherapy
Description: This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spice-Scented Aromatherapy
Description: This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This control is a blend of plant derived oils which have been expressed from crude plant matter.
Study: NCT01100450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: 12-week progressive resistance training (PRT) exercise program
Study: NCT00496028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral tablet
Study: NCT01949909

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TZ Ver
Description: intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TZ Alum 50
Description: intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
Study: NCT04035135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: investigational drug
Study: NCT01949909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TZ GLA 2.5/10
Description: intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TZ GLA5/50
Description: intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
Study: NCT04624854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Aspirin dual-antiplatelet therapy
Description: Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin monotherapy
Description: Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
Study: NCT05536583

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve Gastrectomy
Description: Laparoscopic sleeve Gastrectomy
Study: NCT01949909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TZ GLA2.5/50
Description: intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
Study: NCT03086512

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acutrak 2® - 7.5 Screw
Description: The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Synthes® 7.3 Cannulated Screw
Description: The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
Study: NCT05339971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: block perforation
Description: The bone block used for lateral bone augmentation will be perforated several times.
Study: NCT03931044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-Guided Robotic Gastrectomy
Description: The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.
Study: NCT00930813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lutonix Catheter
Description: Paclitaxel Coated Balloon Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard uncoated Balloon Angioplasty Catheter
Description: plain, uncoated angioplasty balloon catheter